Company news
Pulmatrix, Inc. (NASDAQ:PULM) news
Pulmatrix, Inc. news releases on 6ix. Latest, Nov 9, 2021: Pulmatrix Announces Resolution of Contract Dispute with Cipla
Press releases — page 2
Pulmatrix Announces Resolution of Contract Dispute with Cipla
November 8, 2021
Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update
August 9, 2021
Pulmatrix appoints Director Anand Varadan
July 26, 2021
Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine
April 14, 2021
Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio
April 11, 2021
Pulmatrix Reports 2020 Financial Results and Provides Business Update
March 22, 2021
Pulmatrix Provides a Pipeline and Business Update
March 3, 2021
Pulmatrix Announces Closing of $40 Million Registered Direct Offering
February 15, 2021
Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
February 10, 2021
Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates
November 11, 2020
Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud
October 20, 2020
Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles
September 29, 2020
Pulmatrix Strengthens Board of Directors with Appointment of Todd Bazemore
September 28, 2020
Pulmatrix Reports Progress on Product Pipeline
September 21, 2020
Pulmatrix Reports Q2 2020 Results and Business Updates
August 6, 2020
Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles
July 7, 2020
Pulmatrix Announces Changes to Board of Directors
June 25, 2020
Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually
May 26, 2020
Pulmatrix Reports Q1 2020 Results
May 13, 2020
Pulmatrix Announces $8.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
April 15, 2020
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19
April 15, 2020
Pulmatrix Reports 2019 Financial Results and Provides Business Update
March 25, 2020
Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
January 29, 2020
Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 15, 2020
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
January 1, 2020
Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors
November 3, 2019
Pulmatrix Reports Q3 2019 Results
October 31, 2019
Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma
September 17, 2019
Pulmatrix Receives US Patent Covering iSPERSE(TM) Formulations for Pulmazole Program
August 18, 2019
Pulmatrix Reports Q2 2019 Results
August 4, 2019
Pulmatrix Activates Sites for Pulmazole Phase 2 Clinical Study
July 8, 2019
Pulmatrix Reports Q1 2019 Results
May 14, 2019
Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole(TM)
April 14, 2019
Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering
April 7, 2019
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole
March 31, 2019